Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients

All 178 HIV-infected individuals who had initiated tenofovir-emtricitabine-nevirapine (TDF/FTC/ NVP) at our institution and were adherent to their medication were retrospectively examined. Only 22% were antiretroviral naive. After a median follow-up of 16 months, only five (2.8%) individuals (all with prior exposure to other antiretroviral regimens) experienced virological failure. In all instances, viral rebound occurred after 12 weeks of therapy. These results do not support an increased risk of early virological failure using TDF/FTC/NVP.